• 1.

    Nakai S, et al. An overview of regular dialysis treatment in Japan (as of 31 December 2004). Ther Apher Dial 2006; 10:476497. doi: 10.1111/j.1744-9987.2006.00440.x

  • 2.

    Chembo CL, et al. Long-term outcomes for primary glomerulonephritis: New Zealand glomerulonephritis study. Nephrology (Carlton) 2015; 20:899907. doi: 10.1111/nep.12538

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 3.

    Murugapandian S, et al. Epidemiology of glomerular disease in southern Arizona: Review of 10-year renal biopsy data. Medicine (Baltimore) 2016; 95:e3633. doi: 10.1097/MD.0000000000003633

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 4.

    Haas M, et al. A multicenter study of the predictive value of crescents in IgA nephropathy. J Am Soc Nephrol 2017; 28:691701. doi: 10.1681/ASN.2016040433

  • 5.

    Wyatt RJ, Julian BA. IgA nephropathy. N Engl J Med 2013; 368:24022414. doi: 10.1056/NEJMra1206793

  • 6.

    Reid S, et al. Non-immunosuppressive treatment for IgA nephropathy. Cochrane Database Syst Rev 2011; CD003962. doi: 10.1002/14651858.CD003962.pub2

  • 7.

    Selvaskandan H, et al. New strategies and perspectives on managing IgA nephropathy. Clin Exp Nephrol 2019; 23:577588. doi: 10.1007/s10157-019-01700-1

  • 8.

    Barratt J, Floege J. SGLT-2 inhibition in IgA nephropathy: The new standard of care? Kidney Int 2021; 100:2426. doi: 10.1016/j.kint.2021.04.002

  • 9.

    Wheeler DC, et al. A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy. Kidney Int 2021; 100:215224. doi: 10.1016/j.kint.2021.03.033

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 10.

    Pozzi C, et al. Corticosteroids in IgA nephropathy: A randomised controlled trial. Lancet 1999; 353:883887. doi: 10.1016/s0140-6736(98)03563-6

  • 11.

    Manno C, et al. Randomized controlled clinical trial of corticosteroids plus ACE-inhibitors with long-term follow-up in proteinuric IgA nephropathy. Nephrol Dial Transplant 2009; 24:36943701. doi: 10.1093/ndt/gfp356

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 12.

    Lv J, et al. Combination therapy of prednisone and ACE inhibitor versus ACE-inhibitor therapy alone in patients with IgA nephropathy: A randomized controlled trial. Am J Kidney Dis 2009; 53:2632. doi: 10.1053/j.ajkd.2008.07.029

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 13.

    Rauen T, et al. Intensive supportive care plus immunosuppression in IgA nephropathy. N Engl J Med 2015; 373:22252236. doi: 10.1056/NEJMoa1415463

  • 14.

    Lv J, et al. Effect of oral methylprednisolone on clinical outcomes in patients with IgA nephropathy: The TESTING randomized clinical trial. JAMA 2017; 318:432442. doi: 10.1001/jama.2017.9362

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 15.

    Trimarchi H, et al. Oxford classification of IgA nephropathy 2016: An update from the IgA Nephropathy Classification Working Group. Kidney Int 2017; 91:10141021. doi: 10.1016/j.kint.2017.02.003

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 16.

    Barbour SJ, et al. Evaluating a new international risk-prediction tool in IgA nephropathy. JAMA Intern Med 2019; 179:942952. doi: 10.1001/jamainternmed.2019.0600

  • 17.

    Chen T, et al. Identification and external validation of IgA nephropathy patients benefiting from immunosuppression therapy. EBioMedicine 2020; 52:102657. doi: 10.1016/j.ebiom.2020.102657

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 18.

    Zhang X, et al. A validation study of crescents in predicting ESRD in patients with IgA nephropathy. J Transl Med 2018; 16:115. doi: 10.1186/s12967-018-1488-5

  • 19.

    Schimpf JI, et al. Renal outcomes of STOP-IgAN trial patients in relation to baseline histology (MEST-C scores). BMC Nephrol 2018; 19:328. doi: 10.1186/s12882-018-1128-6

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 20.

    Roccatello D, et al. Steroid and cyclophosphamide in IgA nephropathy. Nephrol Dial Transplant 2000; 15:833835. doi: 10.1093/ndt/15.6.833

  • 21.

    Kanno Y, et al. A comparison of corticosteroid and warfarin therapy in IgA nephropathy with crescent formation: Preliminary trial. Clin Exp Nephrol 2003; 7:4851. doi: 10.1007/s101570300006

    • PubMed
    • Search Google Scholar
    • Export Citation

Glomerular Disease Corner: Managing Crescentic IgA Nephropathy

Haresh Selvaskandan Haresh Selvaskandan, MBChB (Hons), MRCP (UK), ESE (Neph), MRes, BSc (Hons), is a GlomCon Fellow and a Higher Specialist Trainee in nephrology (Nephrology Fellow)/Kidney Research UK Clinical Research Fellow with the John Walls Renal Unit, University Hospitals of Leicester, and Department of Cardiovascular Sciences, University of Leicester, UK.

Search for other papers by Haresh Selvaskandan in
Current site
Google Scholar
PubMed
Close
Restricted access
Save